Cargando…

Cell-free DNA sequencing sheds additional insights on BRCA-altered metastatic castration-resistant prostate cancer

Detalles Bibliográficos
Autores principales:	Bazyar, Soha, Sutera, Philip, Deek, Matthew P., Marshall, Catherine H., Tran, Phuoc T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432590/ https://www.ncbi.nlm.nih.gov/pubmed/37566929 http://dx.doi.org/10.1016/j.ebiom.2023.104756

Ejemplares similares

Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
por: Abida, Wassim, et al.
Publicado: (2020)

Editorial Comment: Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223
por: dos Reis, Rodolfo Borges, et al.
Publicado: (2020)

National Consensus on Non-metastatic Castration-Resistant Prostate Cancer: more than just a snapshot
por: Reis, Leonardo Oliveira, et al.
Publicado: (2021)

The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited
por: Deek, Matthew P., et al.
Publicado: (2021)

Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA
por: Matsubara, Nobuaki, et al.
Publicado: (2023)

Editorial Comment to Tumor lysis syndrome following cabazitaxel administration for metastatic castration‐resistant prostate cancer: A case report
por: Yamamoto, Yoshiyuki
Publicado: (2019)

Multi-Gene Next-Generation Sequencing Panel for Analysis of BRCA1/BRCA2 and Homologous Recombination Repair Genes Alterations Metastatic Castration-Resistant Prostate Cancer
por: Maloberti, Thais, et al.
Publicado: (2023)

Effect of cisplatin on metastatic castration-resistant prostate cancer with BRCA2 mutation: A case report
por: Koguchi, Dai, et al.
Publicado: (2021)

Shedding light on the work burden of long COVID
por: Lemogne, Cédric, et al.
Publicado: (2023)

Editorial Comment from Dr Kato to A case of metastatic treatment‐emergent small cell/neuroendocrine prostate cancer with BRCA2 mutation by liver biopsy
por: Kato, Manabu
Publicado: (2022)

Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report
por: Ma, Yi, et al.
Publicado: (2018)

Utility of plasma cell‐free DNA in metastatic castration‐resistant prostate cancer
por: Hamano, Itsuto, et al.
Publicado: (2020)

Personalized Treatment Approach to Metastatic Castration-Resistant Prostate Cancer with BRCA2 and PTEN Mutations: A Case Report
por: Julka, Pramod Kumar, et al.
Publicado: (2020)

Metastatic Castration-Resistant Prostate Cancer with BRCA2 Mutation: The Challenge Incorporating PARP Inhibitors and Platinum in Treatment Sequencing
por: Nogueira Costa, Inês, et al.
Publicado: (2022)

Differential responses to taxanes and PARP inhibitors in ATM‐ versus BRCA2‐mutated metastatic castrate‐resistant prostate cancer
por: Su, Christopher T., et al.
Publicado: (2022)

Editorial Comment from Dr Sekino and Dr Hinata to A case of metastatic treatment emergent small cell/neuroendocrine prostate cancer with BRCA2 mutation diagnosed by liver biopsy
por: Sekino, Yohei, et al.
Publicado: (2022)

Editorial Comment to Castration‐resistant prostate cancer diagnosed during leuprorelin treatment for spinal and bulbar muscular atrophy
por: Pennuto, Maria, et al.
Publicado: (2022)

Editorial Comment to Nonmetastatic castration‐resistant prostate cancer treated with salvage focal brachytherapy after external beam radiotherapy
por: Hirayama, Yukiyoshi, et al.
Publicado: (2021)

Human molecular genetics sheds light on the physiological significance of ribonuclease inhibitor (RNH1)
por: Sarangdhar, Mayuresh Anant, et al.
Publicado: (2023)

Dynamic changes in gene alterations during chemotherapy in metastatic castrate resistant prostate cancer
por: Tan, Winston, et al.
Publicado: (2022)

Multi-protocol exploratory treatment for metastatic castration-resistant prostate cancer with BRCA mutations: a case report and literature review
por: Zhao, Dongsheng, et al.
Publicado: (2023)

Sequencing technology status of BRCA1/2 testing in Latin American Countries
por: Solano, Angela R., et al.
Publicado: (2020)

Metaplastic breast cancer and BRCA1: first strong evidence of a link
por: Evans, D. Gareth R, et al.
Publicado: (2023)

Utilization and Outcomes of Surgical Castration in Comparison to Medical Castration in Metastatic Prostate Cancer
por: Garje, Rohan, et al.
Publicado: (2019)

New insights for drug resistance in metastatic castration-resistant prostate cancer
por: Kushwaha, Prem Prakash, et al.
Publicado: (2022)

Modulating Mesothelin Shedding to Improve Therapy
por: Zhang, Yujian, et al.
Publicado: (2012)

Editorial Comment to Safety and efficacy of apalutamide in Japanese patients with metastatic castration‐sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo‐controlled, phase III TITAN study
por: Zang, Zhijiang, et al.
Publicado: (2022)

Choices for cancer prevention for women with a BRCA1 mutation? a personal view
por: Narod, Steven A.
Publicado: (2023)

Editorial Comment to Interstitial lung disease induced by apalutamide therapy for castration‐resistant prostate cancer: A report of a rare case
por: Yuasa, Takeshi
Publicado: (2022)

Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer
por: Francini, Edoardo, et al.
Publicado: (2021)

Castration Instead of Lynching
Publicado: (1906)

Metastatic Castration-Resistant Prostate Cancer with Neuroendocrine Transformation and BRCA 1 Germ-Line Mutation: A Case Report and Literature Review
por: Wu, Yinhang, et al.
Publicado: (2020)

Therapeutic sensitivity to standard treatments in BRCA positive metastatic castration-resistant prostate cancer patients—a systematic review and meta-analysis
por: Fazekas, Tamás, et al.
Publicado: (2022)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Shedding new light on COVID-19 therapeutics during the omicron era: a deeper dive into real-world data
por: De Vito, Andrea, et al.
Publicado: (2023)

Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014)

Treatment sequencing in metastatic castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

Abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Mostaghel, Elahe A
Publicado: (2014)

Enzalutamide for patients with metastatic castration-resistant prostate cancer
por: Ramadan, Wijdan H, et al.
Publicado: (2015)

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
por: Rodriguez-Vida, Alejo, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_rpl9snlonf67tc8ljk6rosvh0s